Ovarian cancer

This early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measu…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how m…

This phase 2 trial is investigating whether adding an experimental DNA-based therapy called ELENAGEN to the chemotherapy drug gemcitabine can help people with platinum-resistant ovarian cancer. The study will compare the combination against gemcitabine alone, measuring how long p…

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …

This trial tests an experimental drug, RSO-021, given directly into the chest cavity of people with malignant pleural effusion—a buildup of fluid around the lungs caused by advanced solid tumors or mesothelioma. The study aims to find a safe dose and check for early signs that th…

This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…

This study monitors the safety and effectiveness of the drug olaparib (Lynparza) in people with ovarian, breast, prostate, or pancreatic cancer who are prescribed it as part of routine care in South Korea. Researchers will track side effects and how long the cancer stays under co…

This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This phase II trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) improves outcomes for people with advanced stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. The study aims to s…

This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …

This phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …

This study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Beca…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This study compares a new formulation of the chemotherapy drug doxorubicin (Doxopeg) to the standard version (Caelyx) in people with advanced ovarian cancer or metastatic breast cancer. The goal is to see if the two drugs are absorbed and processed by the body in the same way. Pa…

This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …

This study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…

This early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…

This early-phase study tested whether adding indomethacin, a common anti-inflammatory drug, to standard platinum-based chemotherapy is safe for people with colorectal, esophageal, or ovarian cancers. The 13 participants received escalating doses of indomethacin alongside their ch…

This early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizuma…

This study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from cont…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …

This early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This study tested a special collagen mesh (Surgicoll-Mesh) placed in the abdomen during surgery for cancers that have spread to the lining of the belly. The goal was to see if it could prevent serious problems like bowel blockages, infections, or the need for more surgery. 60 adu…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…

This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that had stopped responding to platinum-based chemotherapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants took the drugs by…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. …

This trial studied 211 women with advanced ovarian cancer who were not candidates for upfront surgery. Researchers compared having surgery after 3 rounds of chemotherapy versus after 6 rounds. The goal was to see which timing leads to longer disease-free survival. All patients re…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could slow cancer progression in women with recurrent platinum-sensitive ovarian cancer. 18 participants took simvastatin alongside carboplatin and liposomal dox…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has come back after at least two prior treatments. The goal was to see if the drug can shrink tumors or slow the cancer's growth. The drug is taken as …

This early-phase trial tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, gastric, pancreatic, or ovarian) that had returned or spread despite prior treatments. The drug is designed to help the immune system attack cancer cells that carry a s…

This phase 2 trial tested a drug called mirvetuximab soravtansine in 79 people with recurrent platinum-sensitive ovarian, peritoneal, or fallopian tube cancers that have high levels of a protein called folate receptor-alpha. The drug is given by IV every three weeks. The main goa…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This early-phase study tested a new drug called SL-172154 combined with either of two standard chemotherapies in 86 people with ovarian cancer that had stopped responding to platinum-based treatment. The main goals were to check safety and find the best dose. Researchers also loo…

This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…

This study tested a new drug called RP903 in 69 people with advanced solid tumors (like ovarian, breast, or cervical cancer) who had run out of standard options. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. It is an early-phase tria…

This study looked at 120 vulnerable women over 70 with advanced ovarian cancer. It compared three chemotherapy plans: standard two-drug therapy every three weeks, a single drug every three weeks, or a weekly two-drug schedule. The goal was to see which plan allowed patients to co…

This study tested whether giving the immunotherapy drug nivolumab directly into the abdomen is safe after extensive surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. 22 adults with recurrent ovarian, peritoneal, or fallopian tube cancer took part. The goal was …

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested whether zafirlukast, an asthma drug, can slow or stop ovarian cancer in people whose only sign of relapse is a rising CA-125 blood marker. Only 5 participants were enrolled. The main goal was to see if the drug could lower CA-125 levels by at least half for a mo…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The r…

This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations an…

This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …

This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…

This phase 2 trial tested whether adding an experimental drug (MK-4830) to standard chemotherapy and pembrolizumab (Keytruda) could better shrink high-grade serous ovarian cancer before surgery. 160 participants with stage III or IV disease received either the standard regimen or…

This Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the ca…

This study tested an experimental drug called ESG401 in 156 people with advanced solid tumors (including breast, lung, and colorectal cancers) who had no other treatment options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. The …

This Phase 3 trial tested whether adding the experimental drug BD0801 to standard chemotherapy can help women with recurrent ovarian cancer that no longer responds to platinum-based treatments. The study enrolled 421 participants and compared the combination to chemotherapy alone…

This phase II trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before surgery helps women with stage IV ovarian cancer. 91 participants received either chemo alone or chemo plus pembrolizumab, followed by surgery. The goal was t…

This early-phase trial tested the combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find a safe dose and check for side effects. Researchers also lo…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This study tests Cellvizio, a device that provides real-time, high-resolution views of tissues during gynecological surgery. Researchers want to see if it can help diagnose lesions and check surgical margins more accurately. The study will enroll 80 women undergoing laparoscopic …

This trial tests whether indocyanine green, a dye injected before surgery, can find sentinel lymph nodes as reliably as the standard technetium-99 radioactive tracer. About 744 adults with various cancers will receive both agents, and surgeons will compare detection rates using a…

This completed Phase 1 study tested a new radioactive imaging agent called [123I]I-DARPIN-Ec1 in 10 people with lung or ovarian cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors on SPECT scans. Researchers compared the new scan resu…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This study looked at whether fluid collected from behind the vagina (culdocentesis) can help diagnose ovarian cancer. Researchers measured tumor markers CA-125 and HE4 in the fluid of 52 women scheduled for surgery. They also checked a urine sample for estrogen ratios. The goal w…

This study tested a new imaging system that uses a fluorescent dye to help surgeons see cancer that has spread to the lining of the abdomen (peritoneum) during surgery. 18 adults with stomach, ovarian, or mesothelioma cancers that had spread to the abdomen were injected with the …

This study tested a light-based technique called Raman spectroscopy to find ovarian cancer in blood and tissue samples. Researchers looked at samples from 160 women with symptoms or undergoing treatment. The goal was to see if this method can help detect cancer earlier and tell t…

This study looked at whether adding a new tumor marker (HE4) and using special scoring systems (ROMA and RMI) can better tell the difference between harmless ovarian cysts and ovarian cancer. Researchers measured CA125 and HE4 levels in 221 women scheduled for ovarian cyst surger…

This study looked at whether adding a special MRI measurement (called ADC) to the standard scoring system helps doctors more accurately tell if ovarian growths are cancerous. Researchers reviewed MRI scans from 66 women with suspicious ovarian lesions found on ultrasound. The goa…

This study followed 40 women at high genetic risk for ovarian cancer due to BRCA mutations or strong family history. One group chose to have their ovaries and fallopian tubes removed to prevent cancer, while the other group opted for regular CA-125 blood tests every 3 months to c…

This study tested whether giving a low dose of esketamine during ovarian cancer surgery could prevent depressive symptoms that often follow. 568 women undergoing cytoreductive surgery received either esketamine or a placebo. Researchers measured depression using a standard questi…

This study tested whether giving heated chemotherapy directly into the abdomen during surgery can improve quality of life for people with advanced ovarian, fallopian tube, or peritoneal cancer. Fifty participants received the treatment after standard chemotherapy. Researchers mea…

This study looks at whether a program called prehabilitation—which helps patients get stronger and healthier before surgery—can lower the chance of problems after surgery for advanced ovarian cancer. About 146 women having surgery for ovarian cancer will take part. The goal is to…

This study tested whether bupropion, a medication that affects brain chemicals, can improve low sexual desire in women who have had breast or gynecologic cancer. About 230 women took either bupropion or a placebo pill for 9 weeks. The main goal was to see if their self-reported s…

This study tested a web-based program to improve quality of life and reduce stress in ovarian cancer survivors. 326 women participated, comparing a mindfulness program to a healthy lifestyle program. The goal was to see if the online programs could help with stress, anxiety, mood…

This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…

This study tested a new way to follow up with gynecologic cancer survivors. Instead of seeing a doctor every time, patients saw a nurse at every other visit and used a smartphone app to help manage their health. The goal was to see if this approach improved self-management skills…

This study developed and tested a smartphone app to help Taiwanese women with gynecological cancer learn about their condition and manage symptoms. 67 women used the app, which included a chatbot and educational content. Researchers measured changes in symptom distress, informati…

This study tested a home-based cognitive training program called BrainHQ in 60 women with gynecologic cancers who had memory or thinking problems after chemotherapy. Participants used the app for about 2.5 hours per week for 10 weeks. The goal was to see if the program was practi…

This study looked at whether a 10-week pelvic physical therapy program is practical for gynecologic cancer survivors who have sexual problems. Twenty survivors were enrolled to see if they could stick with the program and if it improved their sexual function and quality of life. …

This study tested a program called BOLSTER, designed to give extra support to people with gynecologic or gastrointestinal cancers and their caregivers after a hospital stay. The goal was to see if the program was practical and well-liked. 121 adults with complex care needs took p…

This study tested whether acupressure, a technique from Traditional Chinese Medicine, can ease fatigue in ovarian cancer survivors. 171 women who had completed primary cancer treatment were taught to apply pressure to specific points on their bodies daily for six weeks. The study…

This study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…

This study tested whether adding the drug aprepitant to standard anti-nausea medicine helps women with gynecologic cancers (like ovarian or cervical cancer) who are getting chemotherapy. 143 women took part. The goal was to see if the extra drug could better prevent nausea and vo…

This pilot study tested whether a non-invasive brain stimulation technique called tDCS could improve balance and thinking in older women who had chemotherapy for breast cancer. 48 women aged 50-85 took part. The results will show if this approach can help with common side effects…

This early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…

This study tested a mobile app designed to help doctors keep track of symptoms in women with advanced ovarian cancer. Ten patients used the app, which combined their medical records with regular symptom reports. The goal was to see if this information helped the care team make be…

This study adapted a 6-session behavioral therapy called FORT for Turkish breast and ovarian cancer survivors to help them manage fear of cancer recurrence. Researchers worked with 100 participants to translate and test the therapy, measuring changes in fear, anxiety, and quality…

This study looked at whether taking daily vitamin B complex can help prevent or reduce nerve pain (peripheral neuropathy) caused by the chemotherapy drug paclitaxel in women with ovarian cancer. 146 adult women took part. Half took vitamin B pills every day for 6 months while get…

This completed phase 3 trial tested whether taking psyllium husk fiber capsules during pelvic radiation therapy could reduce gut inflammation and urgency symptoms. 354 adults with pelvic cancers (like rectal, prostate, or gynecological) took either fiber or placebo capsules daily…

This study tested whether a smartphone app (HOPE or SMART) paired with a Fitbit could help women with recurrent gynecologic cancer manage symptoms and improve quality of life during chemotherapy. 102 women participated, using the app to track symptoms and receive advice, while we…

This study checks for muscle loss (sarcopenia) in 25 women with advanced ovarian cancer before they start chemotherapy. Using CT scans, researchers want to see how common this condition is and if it affects treatment timing. The goal is to better understand how muscle health rela…

This completed study enrolled 377 individuals and families with a high risk of breast or ovarian cancer due to known or suspected genetic factors. Researchers collected medical records, questionnaires, and biological samples to better understand the disease's natural history and …

This study asks whether measuring circulating endothelial cells (CECs), cells shed from blood vessel walls, can predict how well ovarian cancer patients respond to standard chemotherapy with or without bevacizumab. Researchers will use a standardized flow cytometry method to coun…

This study tests whether giving gynecologic cancer patients a list of questions to ask their doctor improves their confidence, reduces distress, and builds trust. About 70 adults with newly diagnosed or suspected gynecologic cancer will either receive the question list or usual c…

This study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…

This study investigates whether lymph nodes in the lower abdomen, called the inferior epigastric lymph node basin, might be an early stop for ovarian cancer spreading from the peritoneum. Researchers will biopsy these nodes in 20 patients undergoing surgery for ovarian peritoneal…

This study looks at what factors increase the risk of a serious complication called anastomotic leakage after ovarian cancer surgery. Researchers will analyze data from 401 patients to build a prediction model. The goal is to help surgeons identify high-risk patients early and ta…

This study observed over 1,000 Chinese patients with ovarian or prostate cancer who were already taking or starting the drug olaparib. Researchers tracked side effects and how doctors managed them in everyday practice. The goal was to better understand the drug's safety in this s…

This study looks at how proteins in the blood change in women with ovarian cancer as they go through standard treatment. Researchers collected blood samples before surgery, after surgery, and after chemotherapy to see if these protein shifts could give a fuller picture of how the…

This completed study looked at whether a simple blood test (liquid biopsy) can help track breast, ovarian, and endometrial cancers. Researchers analyzed circulating tumor cells in 150 women to see if these cells could predict the risk of cancer spreading or how well treatment wor…

This completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…

This study looked at two ways to help breast and ovarian cancer survivors get genetic counseling: a mailed brochure or a phone call with a health coach. About 668 women took part. The goal was to see which method led more people to actually get genetic counseling or testing. The …

This study looks at whether a score called KELIM can predict how well ovarian cancer patients respond to maintenance treatment with PARP inhibitors after initial chemotherapy. Researchers will analyze data from 243 patients who took part in the PAOLA-1 trial. If KELIM proves usef…

This study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…

This study followed 40 women with cervical, uterine, or ovarian cancer to see how their relationship and sexual communication changed from diagnosis to 3 months after treatment. Participants filled out questionnaires about their sexual activity, desire, and discomfort. The goal w…

This study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a …

This study tested a digital health platform to help people with a hereditary risk of breast and ovarian cancer share their genetic test results with family members. Researchers worked with 128 participants in Switzerland and Korea to see if the tool reduced distress and improved …

This study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …

This study interviewed 12 women diagnosed with gynaecological cancers (ovarian, womb, cervical, vulval, or vaginal) to understand what made them seek help or delay. Researchers focused on embarrassment and other barriers to early doctor visits. The goal is to use these insights t…

This study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …

This study reviewed over 11,000 patients with advanced ovarian cancer to see if hospitals that follow ten specific quality standards for surgery have better outcomes. The research looked at how long patients lived without their cancer getting worse and overall survival. The goal …

This completed study looked at how often joint pain occurs in 71 people with ovarian, colorectal, or lung cancer who were taking the drug bevacizumab. Participants filled out a questionnaire about their joint pain over 6 months. The goal was to better understand this side effect.

This study tested whether a flexible, personalized exercise program is practical for cancer patients receiving chemotherapy. Twenty-one adults with breast, ovarian, or colorectal cancer took part. The main goal was to see if patients would join, attend, and stick with the exercis…

This study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to understand the economic impact …

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at side effects of the drug niraparib (Zedula) in 354 people with ovarian cancer. Participants took niraparib capsules once a day as part of their normal care, and doctors recorded any side effects for one year. The main focus was on serious side effects like lo…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see …

This study looked at 386 women with cervical, uterine, or ovarian cancer to compare standard laparoscopic surgery versus robot-assisted laparoscopic surgery. The goal was to see which approach causes fewer complications within six months after the operation. Researchers tracked s…

This study checked if the cancer drug olaparib causes low folate (folic acid) levels in the blood. Ten women with advanced ovarian or breast cancer participated. Researchers measured folate levels and looked for related drops in hemoglobin. The goal was to understand side effects…

This study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…

This study looked at 30 women with advanced ovarian cancer to count and examine tumor cells found in their blood. The goal was to see if these cells could help predict how the disease might progress or respond to treatment. The results may lead to better ways to monitor the disea…

This completed study followed 40 women who had standard surgery for gynecologic cancers (endometrial, cervical, ovarian, or fallopian tube). Researchers measured changes in quality of life and checked for lower limb lymphedema (leg swelling). The goal was to learn how surgery aff…

This study looked at how a single round of chemotherapy or immunotherapy changes the way the body uses energy and fats in women with gynecologic cancers. Researchers measured breathing and blood markers in 43 participants before and after treatment. The goal was to learn more abo…

This study looked at how behavioral factors, hormones, and natural body chemicals might influence tumor growth in ovarian cancer. Researchers studied 613 women with ovarian cancer to understand these connections. The goal was to gather knowledge, not to test a treatment.

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This completed study looked at how often fallopian tubes are completely removed when women have surgery to remove an ovary and tube (adnexectomy). The goal was to improve the surgical technique to lower the risk of ovarian cancer. 115 women participated, and researchers checked f…

This study looked at whether it's possible to give ovarian cancer patients a special nutrition shake for seven days before their surgery. 23 patients took part to see if they would stick with the program. The goal was just to see if the program was doable, not to measure health b…

This completed study looked at how muscle energy use differs in women with ovarian or endometrial cancer who are losing weight, depending on their body mass index (BMI). Researchers took blood samples, muscle biopsies, and fat tissue from 70 women during surgery. The goal was to …

This study tested if a special dye (ICG) can help surgeons find the first lymph nodes that ovarian cancer might spread to. 48 women having ovary surgery took part. The goal was to see if the dye works well for this purpose, which could help doctors better understand and stage the…

This study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…

This study tested whether saliva samples can be used to remotely monitor cytomegalovirus (CMV) infection in people receiving treatment for ovarian cancer. Researchers compared saliva and blood samples from 49 participants, collected either at the clinic or at home. The goal was t…

This study looked at how women feel and think after getting a personalized estimate of their breast cancer risk. Researchers used a special computer model (BOADICEA) to give each woman a risk score based on her genes. The goal was to see if this personalized information changes h…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study looked at medical records from 509 adults in Taiwan to find out how often advanced cervical, endometrial, and ovarian cancers have a specific marker called HER2 IHC 3+. Researchers also described the patients' health details to better understand who might benefit from …

This study looked back at medical records of 342 women in Europe with advanced ovarian cancer and a BRCA gene mutation. All had taken the drug olaparib (Lynparza) as their first maintenance treatment after initial chemotherapy. Researchers tracked how long patients lived without …

This study followed 102 women with ovarian, fallopian tube, or endometrial cancer through six cycles of standard chemotherapy (carboplatin and paclitaxel). Researchers measured taste changes, muscle loss, and nutritional decline at the start, halfway, and end of treatment. The go…